Effect of Melatonin on Tumor Growth and Angiogenesis in Xenograft Model of Breast Cancer

As neovascularization is essential for tumor growth and metastasis, controlling angiogenesis is a promising tactic in limiting cancer progression. Melatonin has been studied for their inhibitory properties on angiogenesis in cancer. We performed an in vivo study to evaluate the effects of melatonin treatment on angiogenesis in breast cancer. Cell viability was measured by MTT assay after melatonin treatment in triple-negative breast cancer cells (MDA-MB-231). After, cells were implanted in athymic nude mice and treated with melatonin or vehicle daily, administered intraperitoneally 1 hour before turning the room light off. Volume of the tumors was measured weekly with a digital caliper and at the end of treatments animals underwent single photon emission computed tomography (SPECT) with Technetium-99m tagged vascular endothelial growth factor (VEGF) C to detect in vivo angiogenesis. In addition, expression of pro-angiogenic/growth factors in the tumor extracts was evaluated by membrane antibody array and collected tumor tissues were analyzed with histochemical staining. Melatonin in vitro treatment (1 mM) decreased cell viability (p<0.05). The breast cancer xenografts nude mice treated with melatonin showed reduced tumor size and cell proliferation (Ki-67) compared to control animals after 21 days of treatment (p<0.05). Expression of VEGF receptor 2 decreased significantly in the treated animals compared to that of control when determined by immunohistochemistry (p<0.05) but the changes were not significant on SPECT (p>0.05) images. In addition, there was a decrease of micro-vessel density (Von Willebrand Factor) in melatonin treated mice (p<0.05). However, semiquantitative densitometry analysis of membrane array indicated increased expression of epidermal growth factor receptor and insulin-like growth factor 1 in treated tumors compared to vehicle treated tumors (p<0.05). In conclusion, melatonin treatment showed effectiveness in reducing tumor growth and cell proliferation, as well as in the inhibition of angiogenesis.

[1]  D. Cheresh,et al.  Tumor angiogenesis: molecular pathways and therapeutic targets , 2011, Nature Medicine.

[2]  R. Knight,et al.  Detection of migration of locally implanted AC133+ stem cells by cellular magnetic resonance imaging with histological findings , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[3]  Archita Sharma,et al.  Nanoparticle mediated targeting of VEGFR and cancer stem cells for cancer therapy , 2011, Vascular cell.

[4]  S. Cos,et al.  Influence of melatonin on invasive and metastatic properties of MCF-7 human breast cancer cells. , 1998, Cancer research.

[5]  E. Germain,et al.  Nerve growth factor promotes breast cancer angiogenesis by activating multiple pathways , 2010, Molecular Cancer.

[6]  S. Cos,et al.  Melatonin increases p53 and p21WAF1 expression in MCF-7 human breast cancer cells in vitro. , 1999, Life sciences.

[7]  Aleksander S. Popel,et al.  A compartment model of VEGF distribution in blood, healthy and diseased tissues , 2008, BMC Systems Biology.

[8]  L. Montgomery,et al.  Vascular endothelial growth factor and its relationship to the prognosis and treatment of breast, ovarian, and cervical cancer , 2010, Angiogenesis.

[9]  A. Ullrich,et al.  Up-regulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumor angiogenesis. , 1993, Cancer research.

[10]  Mette Jensen,et al.  Tumor volume in subcutaneous mouse xenografts measured by microCT is more accurate and reproducible than determined by 18F-FDG-microPET or external caliper , 2008, BMC Medical Imaging.

[11]  Harris Markomanolaki,et al.  Hypoxia-inducible factor-1α and vascular endothelial growth factor expression in circulating tumor cells of breast cancer patients , 2009, Breast Cancer Research.

[12]  G. Maestroni,et al.  Anti-angiogenic activity of melatonin in advanced cancer patients. , 2001, Neuro endocrinology letters.

[13]  E. Ling,et al.  Increased vascular permeability and nitric oxide production in response to hypoxia in the pineal gland , 2007, Journal of pineal research.

[14]  Arno Lukas,et al.  Linking the ovarian cancer transcriptome and immunome , 2008, BMC Systems Biology.

[15]  C. Cohen,et al.  Expression of melatonin receptors in triple negative breast cancer (TNBC) in African American and Caucasian women: relation to survival , 2012, Breast Cancer Research and Treatment.

[16]  R. Xiu,et al.  Intracellular signaling pathways involved in cell growth inhibition of human umbilical vein endothelial cells by melatonin , 2007, Journal of pineal research.

[17]  Francesco Galli,et al.  Melatonin signaling and cell protection function , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[18]  Marina V Backer,et al.  Molecular imaging of VEGF receptors in angiogenic vasculature with single-chain VEGF-based probes , 2007, Nature Medicine.

[19]  Bartosz Pula,et al.  Expression of melatonin receptor MT1 in cells of human invasive ductal breast carcinoma , 2013, Journal of pineal research.

[20]  S. Hill,et al.  The growth inhibitory action of melatonin on human breast cancer cells is linked to the estrogen response system. , 1992, Cancer letters.

[21]  S. Cos,et al.  Melatonin and Mammary Pathological Growth , 2000, Frontiers in Neuroendocrinology.

[22]  M. Zabel,et al.  Effect of melatonin on cytotoxicity of doxorubicin toward selected cell lines (human keratinocytes, lung cancer cell line A-549, laryngeal cancer cell line Hep-2). , 2007, In vivo.

[23]  Fan Zhang,et al.  Cytokine-mediated deployment of SDF-1 induces revascularization through recruitment of CXCR4+ hemangiocytes , 2006, Nature Medicine.

[24]  M. Dubocovich,et al.  MT1 melatonin receptor overexpression enhances the growth suppressive effect of melatonin in human breast cancer cells , 2002, Molecular and Cellular Endocrinology.

[25]  I. Kang,et al.  Melatonin suppresses tumor progression by reducing angiogenesis stimulated by HIF‐1 in a mouse tumor model , 2013, Journal of pineal research.

[26]  D. Vordermark.  Hypoxia-specific targets in cancer therapy: role of splice variants , 2010, BMC medicine.

[27]  D A Newsome,et al.  Light suppresses melatonin secretion in humans. , 1980, Science.

[28]  Tripp Frasch,et al.  Molecular Mechanisms of Melatonin Anticancer Effects , 2009, Integrative cancer therapies.

[29]  Sung-Hoon Kim,et al.  Melatonin Suppresses the Expression of 45S Preribosomal RNA and Upstream Binding Factor and Enhances the Antitumor Activity of Puromycin in MDA-MB-231 Breast Cancer Cells , 2013, Evidence-based complementary and alternative medicine : eCAM.

[30]  José Maria Soares,et al.  [Melatonin effects on the female genital system: a brief review]. , 2008, Revista da Associacao Medica Brasileira.

[31]  H. Jun,et al.  Recent advances in insulin gene therapy for type 1 diabetes. , 2002, Trends in molecular medicine.

[32]  Vimalkumar A. Patel,et al.  In vivo tumor angiogenesis imaging with site-specific labeled 99mTc-HYNIC-VEGF , 2006, European Journal of Nuclear Medicine and Molecular Imaging.

[33]  Manuel de Jesus Simões,et al.  Efeitos da melatonina no sistema genital feminino: breve revisão , 2008 .

[34]  R. Herbert,et al.  Effect of Melatonin and Linolenic Acid on Mammary Cancer in Transgenic Mice with c-neu Breast Cancer Oncogene , 2000, Breast Cancer Research and Treatment.

[35]  Giuseppe Alberto Di Bella,et al.  Melatonin Anticancer Effects: Review , 2013, International journal of molecular sciences.

[36]  C. Alonso-González,et al.  Melatonin–estrogen interactions in breast cancer , 2005, Journal of pineal research.

[37]  G. Pagès,et al.  VEGF Spliced Variants: Possible Role of Anti-Angiogenesis Therapy , 2011, Journal of nucleic acids.

[38]  M. Bizzarri,et al.  Molecular mechanisms of melatonin’s inhibitory actions on breast cancers , 2012, Cellular and Molecular Life Sciences.

[39]  Lisa Rydén,et al.  Increased gene copy number of KIT and VEGFR2 at 4q12 in primary breast cancer is related to an aggressive phenotype and impaired prognosis , 2012, Genes, chromosomes & cancer.

[40]  Ali S. Arbab,et al.  Changes in Vascular Permeability and Expression of Different Angiogenic Factors Following Anti-Angiogenic Treatment in Rat Glioma , 2010, PloS one.

[41]  A. Fischman,et al.  Technetium-99m-human polyclonal IgG radiolabeled via the hydrazino nicotinamide derivative for imaging focal sites of infection in rats. , 1990, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[42]  S. Zimmer,et al.  Studies of the interactions between melatonin and 2 Hz, 0.3 mT PEMF on the proliferation and invasion of human breast cancer cells , 2001, Bioelectromagnetics.

[43]  Tom Walsh,et al.  Molecular pathology of breast cancer and its application to clinical management , 1997, Cancer and Metastasis Reviews.

[44]  Won-Jun Jang,et al.  Melatonin suppresses tumor angiogenesis by inhibiting HIF‐1α stabilization under hypoxia , 2010, Journal of pineal research.

[45]  H. Rugo,et al.  Triple-Negative Breast Cancer: Role of Antiangiogenic Agents , 2010, Cancer journal.

[46]  D. Blask,et al.  Physiological melatonin inhibition of human breast cancer cell growth in vitro: evidence for a glutathione-mediated pathway. , 1997, Cancer research.

[47]  A. Arbab.  Activation of alternative pathways of angiogenesis and involvement of stem cells following anti-angiogenesis treatment in glioma. , 2012, Histology and histopathology.

[48]  A. Bikfalvi,et al.  Tumor angiogenesis , 2020, Advances in cancer research.

[49]  Aleksander S. Popel,et al.  Pharmacokinetics and pharmacodynamics of VEGF-neutralizing antibodies , 2011, BMC Systems Biology.

[50]  S. Hill,et al.  Melatonin and Associated Signaling Pathways that Control Normal Breast Epithelium and Breast Cancer , 2011, Journal of Mammary Gland Biology and Neoplasia.

[51]  C. Alonso-González,et al.  Regulation of vascular endothelial growth factor by melatonin in human breast cancer cells , 2013, Journal of pineal research.

[52]  S. Mirunalini,et al.  Studies on the Chemopreventive Potential of Melatonin on 7,12- dimethylbenz(a)anthracene Induced Mammary Carcinogenesis in Rats , 2010 .

[53]  G. Semenza,et al.  HIF-1 and tumor progression: pathophysiology and therapeutics. , 2002, Trends in molecular medicine.

[54]  Jong-Wook Park,et al.  Melatonin down‐regulates HIF‐1α expression through inhibition of protein translation in prostate cancer cells , 2009, Journal of pineal research.

[55]  S. Barni,et al.  Modulation of cancer endocrine therapy by melatonin: a phase II study of tamoxifen plus melatonin in metastatic breast cancer patients progressing under tamoxifen alone. , 1995, British Journal of Cancer.

[56]  M. Dubocovich,et al.  MT(1) melatonin receptor overexpression enhances the growth suppressive effect of melatonin in human breast cancer cells. , 2002, Molecular and cellular endocrinology.

[57]  J. Folkman,et al.  Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma. , 1991, The New England journal of medicine.

[58]  C. Alonso-González,et al.  Antiangiogenic effects of melatonin in endothelial cell cultures. , 2013, Microvascular research.

[59]  P. Wen,et al.  Novel anti-angiogenic therapies for malignant gliomas , 2008, The Lancet Neurology.

[60]  A. Arbab,et al.  Human Cord Blood-Derived AC133+ Progenitor Cells Preserve Endothelial Progenitor Characteristics after Long Term In Vitro Expansion , 2010, PloS one.

[61]  B. Teh,et al.  The management of familial breast cancer. , 2000, Breast.

[62]  L. Formigli,et al.  Combined effects of melatonin and all-trans retinoic acid and somatostatin on breast cancer cell proliferation and death: molecular basis for the anticancer effect of these molecules. , 2012, European journal of pharmacology.

[63]  Katherine Holmes,et al.  Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition. , 2007, Cellular signalling.

[64]  R. Xiu,et al.  Melatonin modulates the expression of VEGF and HIF‐1α induced by CoCl2 in cultured cancer cells , 2008, Journal of pineal research.

[65]  Minghua Yu,et al.  Melatonin prevents human pancreatic carcinoma cell PANC‐1‐induced human umbilical vein endothelial cell proliferation and migration by inhibiting vascular endothelial growth factor expression , 2012, Journal of pineal research.

[66]  Honggang Zhang,et al.  Effect and mechanism of melatonin's action on the proliferation of human umbilical vein endothelial cells , 2006, Journal of pineal research.

[67]  Hui Liu,et al.  Role of CD4+CD25+ Regulatory T Cells in Melatonin‐Mediated Inhibition of Murine Gastric Cancer Cell Growth In Vivo and In Vitro , 2011, Anatomical record.

[68]  A. Arbab,et al.  The role of vascular cell adhesion molecule 1/ very late activation antigen 4 in endothelial progenitor cell recruitment to rheumatoid arthritis synovium. , 2007, Arthritis and rheumatism.